Project Grant R41HL184798
Award Date 8/1/26
Completion Date 7/31/27
Dollars Obligated $310K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Amherst, NY 14228, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Emmune Inc. $299,664 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a non-viral gene therapy vector for treating and preventing atherosclerotic cardiovascular disease. Emmune will leverage lipid nanoparticle (LNP) technology to achieve non-immunogenic gene delivery of a therapeutic protein capable of treating and preventing atherosclerosis. The company has discovered a novel approach to...
- The National Heart, Lung, and Blood Institute awarded Duke University $160,040 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 30, 2025, to investigate the ability of an injectable polypeptide scaffold to improve patient outcomes after myocardial infarction. The research focuses on partially ordered polypeptides (POPS), a biomaterial that transitions from an injectable liquid at room temperature to a physically crosslinked, porous network at body temperature. POPS...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $1,540,883 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a new lipid-lowering and anti-inflammatory siRNA therapy for atherosclerosis treatment. The project targets epsin endocytic adaptor proteins through dual-tissue siRNA lipid nanoparticles engineered to simultaneously silence epsins in the liver and atherosclerotic plaques. The approach combines...
- The National Institutes of Health National Heart, Lung and Blood Institute awarded Boston Children's Hospital $1,628,604 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct molecular research on atherosclerosis regulation, with performance through June 30, 2028. The project investigates endothelial dysfunction and chronic inflammation as critical regulators of plaque destabilization in atherosclerosis, focusing on the role of CD47 as a cell-surface...
- The National Heart, Lung, and Blood Institute awarded $799,998 to The Trustees of the University of Pennsylvania on August 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiotropic solid lipid nanoparticles (LNPs) as a drug and biologic delivery platform for cardiac therapeutics. The research focuses on engineering and understanding heart-targeting LNPs that accumulate in cardiac tissue at significantly higher concentrations than existing drug delivery...
- The National Heart, Lung, and Blood Institute awarded 3D Bioanalytix, Inc. $421,400 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance and validate a structural proteomics platform for early detection of protein misfolding–driven cardiovascular diseases. 3D Bioanalytix will optimize and validate the analytical performance and reproducibility of the Amyfold assay, a mass spectrometry–based blood test designed to detect misfolded transthyretin in...
- The National Heart Lung and Blood Institute awarded Brigham & Women's Hospital $1.702 million on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a small activating RNA (saRNA) therapeutic approach for treating atherosclerotic cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis (MASH). The project restores macrophage efferocytosis—the clearance of dead cells—by reactivating the TIM4 receptor on macrophages using...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $820,111 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cell-specific role of the CD40L-CD40 co-stimulatory dyad in modulating atherosclerosis and natural antibody production. The project examines how CD40 expression on B1 cells—innate B cells that produce atheroprotective anti-oxidation-specific-epitope (OSE) immunoglobulin M—protects against atherosclerosis by...
- The National Institute of Biomedical Imaging and Bioengineering awarded $645,265 to The Trustees of The University of Pennsylvania on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop DNA-loaded lipid nanoparticles (DNA-LNPs) for treating chronic diseases including atherosclerosis and emphysema. The research addresses toxicity barriers that have prevented DNA-LNP development for two decades. Prior...
- The National Heart, Lung, and Blood Institute awarded New York University's Long Island School of Medicine $2.728 million on September 24, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on reducing plasma cholesterol and atherosclerosis using C2, a synthetic microRNA-30c analog. The research will elucidate molecular mechanisms by which C2 administration reduces plasma cholesterol levels in mice with diet-induced hypercholesterolemia and LDL receptor...